

Prior Authorization Request Form Fax Back To: (866) 940-7328 Phone: (800) 310-6826

Specialty Medication Prior Authorization Cover Sheet

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to www.uhcprovider.com for medication fax request forms.)

Patient Information						
Patient's Name:						
Insurance ID:	Date of Birth:	Height: Weight:				
Address:		Apartment #:				
City:	State:	Zip Code:				
Phone Number:	Alternate Phone:	Sex: ☐ Male ☐ Fem	ale			
Provider Information						
Provider's Name:	Provider ID Number:					
Address:	City:	State: Zip Code:				
Suite Number:	Building Number:					
Phone Number:	Fax number:					
Provider's Specialty:						
Medication Information						
Medication:	Quantity:	ICD10 Code:				
Directions:	Diagnosis:	Refills:				
Physician Signature**:		Initial here if DAW:				
Physician Signature**: By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.						
Medication Instructions						
Medication Instructions Has the patient been instructed on how to Self-A	Administer?	☐ Yes ☐ No				
	Administer?	☐ Yes ☐ No				
Has the patient been instructed on how to Self-						
Has the patient been instructed on how to Self- Is this medication a New Start?	Initiation Date: / /	☐ Yes ☐ No				
Has the patient been instructed on how to Self-Alls this medication a New Start? If continuation please provide the following: Is there documentation of positive clinical reserved: **Please attach any pertinent clinical informational clinical information may be needed previously tried and failed.	Initiation Date: / / sponse to current therapy? ation that would pertain to su	☐ Yes ☐ No Date of Last Dose: / / ☐ Yes ☐ No pport stated diagnosis.	n(s)			
Has the patient been instructed on how to Self-Alls this medication a New Start? If continuation please provide the following: Is there documentation of positive clinical research any pertinent clinical informational clinical information may be needed.	Initiation Date: / / sponse to current therapy? ation that would pertain to su	☐ Yes ☐ No Date of Last Dose: / / ☐ Yes ☐ No pport stated diagnosis.	n(s)			
Has the patient been instructed on how to Self-Alls this medication a New Start? If continuation please provide the following: Is there documentation of positive clinical reserved: **Please attach any pertinent clinical informational clinical information may be needed previously tried and failed.	Initiation Date: / / sponse to current therapy? ation that would pertain to sued depending on your patient ian Signature" above and comformation"	☐ Yes ☐ No Date of Last Dose: / / ☐ Yes ☐ No pport stated diagnosis. s plan, including medication plete	n(s)			
Has the patient been instructed on how to Self-Alls this medication a New Start? If continuation please provide the following: Is there documentation of positive clinical reservity the self-Alls and pertinent clinical informational clinical information may be needed previously tried and failed. Delivery Instructions Note: Delivery coordination requires a "Physical "Provider Information" and "Patient Information" and "Patient Information" and "Patient Information"	Initiation Date: / / sponse to current therapy? Ation that would pertain to sued depending on your patient ian Signature" above and comformation" ided free of charge to the patient	☐ Yes ☐ No Date of Last Dose: / / ☐ Yes ☐ No pport stated diagnosis. s plan, including medication plete at at the time of delivery	n(s)			



Iressa - Washington

PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826.

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A – Member Informat	ion						
First Name:					Member ID:		
Address:							
City:		State:			ZIP Code:		
Phone:		DOB:			Allergies:		
Primary Insurance Information:							
Is the requested medication \square	New or □ C	Continuati	on of Therapy? If	continuation, lis	t star	t date:	
Is this patient currently hospi	talized? 🗆	Yes 🗆 No	If recently discha	arged, list disch	arge	date:	
Section B - Provider Informat	ion						
First Name:			Last Name:				M.D./D.O.
Address:			City:		State):	ZIP code:
	ax:		NPI #:		Spec	ialty:	
Office Contact Name / Fax atte	ntion to:						
Section C - Medical Informati	on						
Medication:					Si	rength:	
Directions for use:					Q	uantity:	
Diagnosis (Please be specific	& provide as	much info	rmation as possible	e):	IC	D-10 COD	DE:
Is this member pregnant? Yes No If yes, what is this member's due date?							
		, ,	o, what is this mon	iber 5 due date	'		
Section D – Previous Medicat	ion Trials					Reaso	on for failure /
	ion Trials	ngth	Directions	Dates of The			on for failure /
Section D – Previous Medicat	ion Trials						
Section D – Previous Medicat	ion Trials						
Section D – Previous Medicat	ion Trials						
Section D – Previous Medicat	ion Trials						
Section D – Previous Medications Medications	ion Trials Stre	ngth	Directions	Dates of The	erapy	disc	continuation
Section D – Previous Medicat Medications Section E – Additional informa	ion Trials Stre	ngth	Directions	Dates of The	erapy	disc	e patient's needs:
Section D – Previous Medicat Medications Section E – Additional informa	ion Trials Stre	ngth	Directions of why preferred r	Dates of The	erapy	disc	e patient's needs:
Section D – Previous Medicat Medications Section E – Additional informa	ion Trials Stre	ngth	Directions of why preferred r	Dates of The	erapy	disc	e patient's needs:
Section D – Previous Medicat Medications Section E – Additional informa	ion Trials Stre	ngth	Directions of why preferred r	Dates of The	erapy	disc	e patient's needs:
Section D – Previous Medicat Medications Section E – Additional informa	ion Trials Stre	ngth	Directions of why preferred r	Dates of The	erapy	disc	e patient's needs:
Section D – Previous Medicat Medications Section E – Additional informa	ion Trials Stre	ngth	Directions of why preferred r	Dates of The	erapy	disc	e patient's needs:
Section D – Previous Medicat Medications Section E – Additional informa	ion Trials Stre	ngth	Directions of why preferred r	Dates of The	erapy	disc	e patient's needs:
Section D – Previous Medicat Medications Section E – Additional informa	ion Trials Stre	ngth	Directions of why preferred r	Dates of The	erapy	disc	e patient's needs:
Section D – Previous Medicat Medications Section E – Additional informa	ion Trials Stre	ngth	Directions of why preferred r	Dates of The	erapy	disc	e patient's needs:



Physician Signature:

Iressa - Washington

PRIOR AUTHORIZATION REQUEST FORM

Date: _

Member Firs	t name:	Member Last name:	Member DOB:				
Clinical and Drug Specific Information							
ALL REQUESTS							
□ Yes □ No	Does the patient have one of the following diagnoses? (If yes, check which applies) □ Metastatic or recurrent non-small cell lung cancer (NSCLC) □ Recurrent central nervous system (CNS) cancer						
□ Yes □ No Is the requested use of Iressa supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium? If yes, List supported use:							
NON-SMALL CELL LUNG CANCER							
□ Yes □ No	Are tumors positive for epidermal growth factor receptor (EGFR) exon 19 deletions?						
□ Yes □ No	Are tumors positive for exon 21 (L858R) substitution mutations?						
□ Yes □ No	Are tumors positive for a known sensitizing EGFR mutation (e.g., in-frame exon 20 insertions, exon 18 G719 mutation, exon 21 L861Q mutation)?						
CENTRAL NERVOUS SYSTEM (CNS) CANCERS							
□ Yes □ No	Does the patient have metastatic lesions?						
□ Yes □ No	Is Iressa active against primary (NSCLC) tumor with a known EGFR sensitizing mutation?						
CONTINUATION OF THERAPY							
□ Yes □ No	Does the patient show e	vidence of progressive disease while o	n Iressa therapy?				
□ Yes □ No	Is there documentation of the season of the	of positive clinical response to Iressa t	herapy?				

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.